ENANTA PHARMACEUTICALS INC Cash Flow Statement
ENTA|13 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
ENANTA PHARMACEUTICALS INC used $103M in operating cash flow and negative free cash flow of $112M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$133.8M | -$121.8M | -$79.0M | -$36.2M | $46.4M | $72.0M | $17.7M | $21.7M | $79.0M | $34.4M | $9.6M | $21.4M | $23.3M |
| Depreciation & Amortization | $2.4M | $3.0M | $3.3M | $3.6M | $3.3M | $2.5M | $2.1M | $1.7M | $639.0K | $352.0K | $221.0K | $172.0K | $499.0K |
| Operating Cash Flow | -$103.2M | -$84.8M | -$70.0M | $7.1M | $71.4M | $29.2M | $52.7M | $35.8M | $76.7M | $20.2M | $10.7M | $22.6M | $24.0M |
| Capital Expenditures | $9.1M | $2.1M | $750.0K | $1.4M | $5.4M | $3.0M | $2.5M | $4.7M | $2.3M | $1.0M | $606.0K | $252.0K | $445.0K |
| Free Cash Flow | -$112.2M | -$86.9M | -$70.7M | $5.6M | $66.0M | $26.2M | $50.1M | $31.1M | $74.3M | $19.2M | $10.0M | $22.4M | $23.6M |
| FCF Margin | -141.7% | -100.9% | -72.9% | 4.6% | 32.2% | 12.7% | 48.8% | 35.2% | 46.2% | 40.1% | 31.3% | 53.6% | 56.3% |